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Abstract
Purpose: To evaluate the impact of including a medicine in the list of medicinal prod-
ucts subject to additional monitoring (AM) on the reporting of adverse drug reactions
(ADRs) in the european economic area (EEA).
Methods: Interrupted time series using the monthly number of EEA ADR reports in
EudraVigilance during 12 months before and after the addition to AM list. The main
outcome was the change (%) in reporting of ADRs with step change as the a priori
impact model. Further time series analysis was performed using Joinpoint Regression.
Results: The analysis included 11 active substances. No significant immediate (step
change) increase of reporting was identified for any product at time of addition to AM
list. We identified a significant gradual increase of ADR reporting after addition to AM
list (slope change) for two out of five new products—boceprevir (10% per month, 95%
confidence interval (CI) 3%–18%) and denosumab-Xgeva (13% per month, 95% CI 4%–
22%). No change was identified for Prolia, another denosumab-containing product not
subject to AM. No significant increase was identified for any product included in the
AM list due to the requirement to conduct a PASS. Conversely, a gradual decrease in
reporting was identified for natalizumab (−5% per month; 95% CI −10% to −1%),
rivaroxaban (−5%; −8 to −3%), and varenicline (−16%; −21 to −10%). The results were
corroborated by the Joinpoint analyses, which yielded similar results.
Conclusions: We identified limited evidence that reporting of ADRs increased modestly
and gradually for some new products and not for products with PASS requirement.
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1 | INTRODUCTION
Pharmacovigilance is the science and activities relating to the detec-
tion, assessment, understanding and prevention of adverse drug reac-
tions (ADRs) or any other medicine-related problem.
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Pharmacovigilance contributes to the protection and promotion of
public health, timely access to innovative medicines and their safe and
effective use after authorisation. Reporting of suspected ADRs is the
cornerstone of pharmacovigilance as regular monitoring of newly
received reports allows the identification of new risks and changes in
known risks for medicines. Additional monitoring (AM) was introduced
in Europe in 2010, following the revision of pharmacovigilance legisla-
tion (Regulation [EC] No 726/2004, Article 23), to increase the
reporting of ADRs for targeted medicines.1,2
Medicines falling under the mandatory scope of additional moni-
toring include new medicines, new biologicals, medicines authorised
subject to conditions or under exceptional circumstances, and medi-
cines with the obligation to conduct a post-authorisation safety study
(PASS). Such medicines are identified with an inverted black triangle
and an accompanying explanatory statement in their product informa-
tion and are included in the list of medicines under additional monitor-
ing which is updated and published monthly (AM list). Once on the
list, a medicine will remain under additional monitoring for 5 years or
until removed from the list by the Pharmacovigilance Risk Assessment
Committee (PRAC). The black triangle allows to quickly identify medi-
cines that are subject to additional monitoring and encourages
patients and healthcare professionals to report any ADRs. At the end
of 2019, 342 medicines were included in the AM list.2-4
The impact of additional monitoring as a policy intervention on the
reporting of ADRs is unknown. Measuring the impact of regulatory deci-
sions is important for all pharmacovigilance activities in order to improve
existing processes.5,6 Consequently, we undertook this study using
EudraVigilance data to investigate whether the inclusion of medicines in
the AM list increases the reporting of ADRs for those medicines in Europe.
The study was part of a data gathering project on the experience with
additional monitoring, together with a survey of patients' and healthcare
professionals' attitudes and behaviours towards reporting ADRs.1,7
2 | METHODS
2.1 | Data sources
Information on the number of reported ADRs was obtained from
EudraVigilance, the European database of ADR reports maintained by
the european medicines agency (EMA) on behalf of the EU network,
which at the end of 2018 contained over 14.5 million reports of
suspected ADRs.8-10
2.2 | Exposures
Eligible medicines were identified from the December 2015 version of
the AM list,3 by excluding those which did not have 12 months of
authorised use prior to their addition to the list (to ensure we had a
baseline of reporting for comparison) and those medicines for which
their monthly reporting of ADRs from the EEA was less than
10 reports (over the 24 months of observation).
For each substance, we obtained the monthly number of post-
marketing individual case reports of ADRs originating from the EEA
from EudraVigilance,8-10 the EU database of ADR reports, for
12 months prior to and 12 months after inclusion of the product in
the AM list (the intervention).
To account for changes in the number of patients exposed to the
medicines over time, we calculated the size of at-risk population using
medicine consumption/exposure data estimates obtained from Peri-
odic Safety Update Reports11 (PSUR) held by EMA for centrally-
authorised products. Exposure data are normally reported as the total
person-years exposed during the interval covered by the PSUR which
can range from 6 months to several years. We therefore divided the
person-years by the number of years covered by a PSUR period and
smoothed the data over time using a piecewise linear form between
the mid-point intervals. Where PSUR data were not available for the
whole period under observation, but was missing only for a few
months, we imputed the modelled exposure to the missing months
based on the period with available data, as a continuation of that
trendline. For products for which PSUR data was not available, we
substituted the estimates of exposure by defined daily dose from pub-
licly available nationwide drug consumption databases available from
Denmark,12 France,13 Netherlands,14 Norway,15 Sweden16 and United
Kingdom,17 representing approx. 30% of the EU population.
2.3 | Analysis
Interrupted time series (ITS) is a suitable analytical method for evalu-
ating the effect of interventions implemented at population level at a
KEY POINTS
• EU legislation mandates that new medicines including
new biologicals, medicines authorised subject to condi-
tions or under exceptional circumstances and medicines
with the obligation to conduct a post-authorisation safety
study (PASS) are subject to additional monitoring aimed
at increasing the reporting of ADRs by patients and
healthcare providers.
• The real impact of additional monitoring on reporting of
ADRs is currently unknown.
• Using an interrupted time series analysis of
EudraVigilance ADR reporting data, we identified limited
evidence that reporting of ADRs increased modestly and
gradually for some new products. In contrast, reporting of
ADRs did not increase (or even decreased) for products
subject to AM due to the requirement to conduct
a PASS.
• Further work is required to determine the effectiveness
of AM as a policy intervention.
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defined time point.18 We applied segmented regression analysis to
the interrupted time series data using Poisson regression and model-
ling the count of events per month, whilst offsetting the changes in
at-risk population. To account for over-dispersion of the data we
corrected the standard error by applying a scale parameter based on
Pearson chi-square statistic divided by the residual degrees of free-
dom and we adjusted for seasonality using Fourier terms with two
pairs of sine/cosine functions.18,19 We postulated an immediate effect
(step change) as our a priori impact model; we also investigated a pos-
sible gradual change in trend (slope change). STATA (College Station,
Texas, USA) version 15 was used for the analyses.
Further time series analysis was performed in parallel using Joinpoint
Regression Program20 (National Cancer Institute, Maryland, USA) version
4.5.0.1, using the Grid search method and Permutation testing. Statistical
analysis using joinpoint regression identifies the time point(s) where a
marked change in trend (the ‘joinpoint’) has occurred and estimates the
regression function compared with the previously identified joinpoints.
As the final number of joinpoints is established on the basis of a statisti-
cal criterion and their position is not fixed it does not require that an
intervention date is pre-specified unlike interrupted time series regres-
sion.21 We compared the results of both statistical analyses.
3 | RESULTS
We identified 82 eligible products corresponding to 79 substances
from the AM list with at least 12 months of baseline data and
excluded 68 substances with low ADR reporting. The final analysis
therefore contained 11 substances, five of which were included in the
AM list due to new substance status (boceprevir, telaprevir,
vemurafenib, fingolimod and denosumab) and six that were included
because of an imposed PASS (imatinib, lenalidomide, natalizumab,
rivaroxaban, valproic acid and varenicline), as detailed in Flowchart 1
and Table 1. Analyses were performed at substance level except for
denosumab, for which we identified two products with different indi-
cations (Xgeva and Prolia) and discrepant AM status. Xgeva is
indicated for the prevention of skeletal related events in adults with
advanced malignancies involving the bone and for the treatment of
giant cell tumour of bone and is subject to AM.22 Prolia is indicated
for the treatment of osteoporosis and for bone loss associated with
hormone ablation in men with prostate cancer and is not subject to
AM.23 The analysis of these products was performed separately at
product level with Prolia used as a control for Xgeva.
As presented in Table 2 and Figures 1 and 2, we did not identify a
significant immediate effect (step change) for any studied product
based on ITS analysis. We identified a significant increase of ADR
reporting as a gradual change in trend after the addition to AM list
(slope change) for boceprevir (10% per month, 95% CI 3%–18%) and
denosumab-Xgeva (13% per month, 95% CI 4%–22%). No significant
change in slope was identified for the other new substances (telaprevir,
vemurafenib and fingolimod). No significant change (step or slope) was
identified for imatinib, lenalidomide and valproate. Conversely, for three
products included in the AM list due to the requirement to conduct a
PASS, we identified a decrease in the reporting of ADRs after addition
to the list (slope decrease): natalizumab (−5% per month, 95% CI −10%
to −1%), rivaroxaban (−5% per month, 95% CI −8% to −3%) and var-
enicline (−16% per month, 95% CI −21− to −10%).
When the two denosumab-containing products were compared,
the reporting for Xgeva, a product that was subject to AM, increased
by 13% (95% CI 4%–22%) per month, but we detected no significant
changes in reporting of ADRs for Prolia (0%, 95% CI −6% to 7%), a
product that was not subject to AM.
The results were broadly comparably with the results of the
Joinpoint analyses, which are presented in Figures 3 and 4, with the
exception of natalizumab, for which no change was identified in
the Joinpoint analysis.
4 | DISCUSSION
In our study we identified that ADR reporting increased after addition
to the AM list for two out of five new products, in the order of 10%–
79 substances (82 medicinal products)
with 12 months authorised use prior to 
addition to AM list
11 substances (11 products*)
included in analysis
5 substances included in AM list due 
to new substance status 
6 substances included in AM list due 
to PASS requirement
68 substances excluded due to 
monthly count of ADR reports from
the EEA less than 10 reports
FLOWCHART 1 Selection of substances for
the study. *Count includes valproic acid as one
product and does not include denosumab-Prolia
(used as control)
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13% per month. For products included in the AM list due to the
requirement for a PASS we identified either no changes or a decrease
in the reporting of ADRs, in the order of −5 and −16% per time point.
For denosumab, the only medicine that had two products with differ-
ing AM status, we observed a 13% increase in reporting for Xgeva,
with no changes observed for Prolia (used as a control for Xgeva),
which is compatible with an effect of additional monitoring. The
results were broadly comparable with the results of the Joinpoint
regression analysis.
This is to our knowledge the first study evaluating the impact of
additional monitoring on the reporting of ADRs. Studies have previ-
ously reported that ADRs for medicines are under-reported, including
for medicines subject to additional monitoring, and including serious
and fatal ADRs.24-27 Such information is vital for pharmacovigilance
decision making. Unequal and sometimes low awareness of additional
monitoring amongst healthcare professionals was reported as poten-
tial reasons for this.28 Our separate study of the knowledge of and
attitudes to ADR reporting found that although 88% of respondents
would report an ADR for a medicine subject to AM, identified with a
black triangle, 1 in 5 reporters misunderstood the concept of AM and
only 37% of those who reported an ADR for a product subject to AM
were influenced by the AM status.1 These factors could partially
TABLE 1 Characteristics of medicinal products included in the study
Active
substance Product name Indications/therapeutic area (MeSH)
Date of inclusion in the
AM list
Reason for inclusion in the
AM list
Boceprevir Victrelis Hepatitis C, chronic April 2013 New active substance
Telaprevir Incivo Hepatitis C, chronic April 2013 New active substance
Vemurafenib Zelboraf Melanoma April 2013 New active substance
Fingolimod Gilenya Multiple sclerosis April 2013 New active substance, PASS
Denosumab Xgeva •Fractures, bone
•Neoplasm metastasis
April 2013 New biological
Prolia (control for
Xgeva)
•Bone resorption
•Osteoporosis, Postmenopausal
N/A N/A
Imatinib Glivec •Precursor cell lymphoblastic leukaemia-
lymphoma
•Gastrointestinal stromal tumours
•Dermatofibrosarcoma
•Myelodysplastic-myeloproliferative
diseases
•Leukaemia, myelogenous, chronic, BCR-
ABL positive
•Hypereosinophilic syndrome
September 2014 PASS
Lenalidomide Revlimid •Multiple myeloma
•Lymphoma, mantle-cell
•Myelodysplastic Syndromes
June 2014 PASS
Natalizumab Tysabri Multiple sclerosis April 2013 PASS
Rivaroxaban Xarelto •Arthroplasty, replacement
•Venous thromboembolism
July 2013 PASS
Valproic acid Various •Bipolar disorder
•Epilepsy
•Migraine disorders
January 2015 PASS
Varenicline Champix Tobacco use cessation April 2013 PASS
TABLE 2 Summary of results—interrupted time series analysis of
the monthly reporting of post-marketing ADRs from the EEA
Active substance Step change Slope change
RR (95% CI) RR (95% CI)
Boceprevira 0.59 (0.23–1.55) 1.10 (1.03–1.18)
Telaprevira 0.85 (0.35–2.06) 1.02 (0.96–1.09)
Vemurafeniba 0.90 (0.38–2.11) 0.96 (0.89–1.02)
Fingolimoda 1.14 (0.74–1.75) 0.97 (0.94–1.00)
Denosumaba—Xgeva 0.73 (0.30–1.77) 1.13 (1.04–1.22)
Denosumaba—Prolia (not in
the AM list, control for
Xgeva)
1.43 (0.62–3.28) 1.00 (0.94–1.07)
Imatinibb 0.78 (0.42–1.42) 1.03 (0.99–1.08)
Lenalidomide 1.54 (0.71–3.53) 1.03 (0.98–1.10)
Natalizumab 0.96 (0.49–1.87) 0.95 (0.90–0.99)
Rivaroxaban 1.30 (0.92–1.85) 0.95 (0.92–0.97)
Valproic acidb 0.91 (0.50–1.67) 1.01 (0.97–1.06)
Varenicline 0.96 (0.42–2.23) 0.84 (0.79–0.90)
aNew medicines.
bAnalysis using exposure data from prescription databases (PSUR data not
available).
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explain the limited effect we found on increasing the reporting
of ADRs.
Due to methodological limitations, the maximum number of sub-
stances that we were able to include in our study (11 of 79 sub-
stances) was limited by the availability of their baseline data or low
reporting, which restricts the overall generalisability of the findings. A
large number of new medicines were excluded simply because there
was no comparative data available before their inclusion in the AM
list. The small sample of substances that we were able to study is also
limited in terms of chemical/biological and pharmacological classes
and may therefore not be universally generalisable to all medicines
subject to AM. A possible solution to overcome this limitation would
be to stagger future implementation of such policy interventions in
various regions over time, which would serve as comparators in a
step-wedge type of approach, but this may not be feasible for EU
wide interventions. Alternatively, where possible, a controlled ITS
design can be used, as illustrated with the denosumab example.
Another approach that could be employed would be to study the
F IGURE 1 Interrupted time series analysis. New products included in the study. Reporting of post-marketing ADRs from the EEA. Green
vertical line: addition to AM list. Red line: predicted reporting from seasonality-adjusted model. Dashed line: de-seasonalised trend
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change in reporting at the time of removal of products from the
AM list.
Our study focused on changes during 12 months after the addi-
tion to AM list. For products already on the market which newly
acquire additional monitoring status, it may take several months or
years for the medicines with the updated product information to
reach patients (medicines already distributed are not re-labelled). It is
therefore possible that a longer follow-up period may be needed to
detect significant changes, if awareness of the AM status increases
slowly and gradually. Considering that no step change was observed
in our study, this remains a possibility. Longer follow up would also
allow studying whether any observed increases are sustained or tem-
porary and thus whether immediate changes and long-term patterns
differ. However, as ITS examines associations only, this would be at
the risk that other interventions including regulatory interventions,
may confound the interpretation over time.
Additionally, the monthly counts of ADR reports were generally
low. This combined with 24 time points and unequal variability in the
monthly reports, restricted the power to detect a difference, as well as
the utility of seasonality adjustment. Due to the small number of
F IGURE 2 Interrupted time series analysis. Products included in the study due to the requirement to conduct a PASS. Reporting of post-
marketing ADRs from the EEA. Green vertical line: addition to AM list. Red line: predicted reporting from seasonality-adjusted model. Dashed
line: de-seasonalised trend
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F IGURE 3 Joinpoint regression analysis—new products included in the study. Reporting of post-marketing ADRs from the EEA, addition to
AM list is at time point 12 (time in months)
SEGEC ET AL. 7
F IGURE 4 Joinpoint regression analysis—products included in the study due to PASS requirement. Reporting of post-marketing ADRs from
the EEA, addition to AM list is at time point 12 (time in months)
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substances which we were able to study as well as the low monthly
ADR counts we were unable to stratify the analyses by the reason of
addition to AM list, by country, or by reporter type (patients or
healthcare professionals) as initially intended. Therefore although differ-
ences in ADR reporting may exist between different reporter types, as
reported in our separate study on reporter attitudes and behaviours,1
we could not examine this effect in this study. Seven of the studied
substances were included in the first version of the list in April 2013
and the remaining four between 2013 and 2015. Therefore, changes in
these reporting sub-categories and changes over time cannot be
excluded.
The application of ITS methods to medicine use data, other than
being limited by the lack of baseline data for new medicines, also
requires reliable estimates of exposure data due to the often rapid
changes in the size of the population at risk, as opposed to population
studies. Medicine use can increase rapidly after authorisation/reim-
bursement and inclusion in clinical guidelines or decrease due to
safety concerns or replacement with a more effective, safer or more
convenient competitor. The estimates of exposure that we have relied
on are often based on approximations from sales data using an
expected dose and treatment duration11 and can therefore be impre-
cise and be a source of residual confounding as well as distort impor-
tant trends.
Other influences in the changes in exposure, especially if they
also relate to the reporting of ADRs would be equally obscured by
such calculations and cannot thus be investigated. Similarly, the
absence of knowledge of other time-varying confounders and their
exact timing, for example, media attention to the results of a study
suggesting the risk of serious ADRs, direct healthcare professional
communication, restrictions in authorised use due to ADRs,
increased awareness due to changes in the international or
national treatment guidelines and precautions/screening at treat-
ment initiation or recommendations for regular testing, and so on,
which may have influenced the reporting of ADRs, can further
complicate the interpretation of time series analyses or lead to
unmeasured confounding. Additionally, patients who are at the
highest risk of an adverse outcome may no longer be treated after
such regulatory actions, and thus the occurrence of ADRs decreases.
We did not collect details about the lifecycle of individual medicines
included in our study, and therefore couldn't investigate these factors
in the current study.
Indeed, half of the substances included in our study were included
in the AM list due to the obligation to conduct a PASS. The imposition of
a PASS often follows the emergence of serious ADRs, concerns about
medicine safety or the evaluation of benefit–risk balance by the PRAC
(e.g. via a referral procedure), with consequent media attention. Such a
setting is prone to confounding due to other regulatory actions and
media attention possibly influencing ADR reporting and therefore the
results are difficult to interpret in terms of causality. This may be one rea-
son why we observed a fall in ADR reporting for several products added
to the AM list due to an imposed PASS. However, should this observa-
tion be confirmed in future research, it may serve to inform any future
discussions on the legislation governing additional monitoring.
5 | CONCLUSION
In summary, we identified limited evidence that reporting of ADRs
increased modestly and gradually for some new products and did not
increase for products subject to AM due to the requirement to conduct
a PASS. The small number of medicines that we were able to include in
our study, together with its ecological design, makes the causality of
this observation difficult to establish. We suggest that, in the future it
would be worthwhile to pre-specify the methods for the evaluation of
policy interventions such as the introduction of additional monitoring,
to help overcome the shortcomings of a retrospective evaluation. Given
the limitations in our results, we would welcome suggestions from the
research and regulatory communities on complementary methods that
might be applied to study the impact of AM.
ETHICAL STATEMENT
The study did not involve human subjects and relied on routine data.
ACKNOWLEDGMENTS
We are grateful to the members of the EMA's Pharmacovigilance Risk
Assessment Committee for their comments on the design of this
study. We are also grateful to Dr Georgy Genov for helpful comments
on the study outline and draft article. The work presented in this arti-
cle did not receive project funding or grants.
Prior postings, sponsors and grants: Partial results were included
in the European Commission report7 (which has since been published).
DRM has received funding support from the Wellcome Trust, NIHR,
Chief Scientist Office and Tenovus Scotland for research unrelated to
this work.
CONFLICT OF INTEREST
The authors have no conflict of interest to declare.
ORCID
Andrej Segec https://orcid.org/0000-0003-2881-0593
Jim Slattery https://orcid.org/0000-0002-8352-9350
Daniel R. Morales https://orcid.org/0000-0002-0063-8069
Justina Januskiene https://orcid.org/0000-0001-6758-650X
Xavier Kurz https://orcid.org/0000-0002-9838-7754
Peter Arlett https://orcid.org/0000-0002-6640-0117
REFERENCES
1. Januskiene J, Segec A, Slattery JM, et al. What are the patients' and
health care professionals' understanding and behaviors towards adverse
drug reaction reporting and additional monitoring? Pharmacoepidemiol
Drug Saf. 2020 Oct 25. https://doi.org/10.1002/pds.5162.
2. Regulation (EC) No 726/2004 of the European Parliament and of the
council of 31 March 2004 laying down Community procedures for
the authorisation and supervision of medicinal products for human
and veterinary use and establishing a European Medicines Agency,
Official Journal L – 136, 30/04/2004, p. 1–33. https://eur-lex.
europa.eu/legal-content/EN/TXT/?uri=celex:02004R0726-
20190128. Accessed April 30, 2019.
3. European Medicines Agency. List of medicines subject to additional
monitoring, EMA/245297/2013 Rev.60. https://www.ema.europa.
SEGEC ET AL. 9
eu/en/human-regulatory/post-authorisation/pharmacovigilance/
medicines-under-additional-monitoring/list-medicines-under-
additional-monitoring. Accessed January 17, 2020.
4. European Medicines Agency. Guideline on good pharmacovigilance
practices Module X – additional monitoring. http://www.ema.europa.
eu/docs/en_GB/document_library/Scientific_guideline/2013/04/
WC500142282.pdf. Accessed April 30, 2019.
5. Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the
impact of medicines regulatory interventions—systematic review
and methodological considerations. Br J Clin Pharmacol. 2018;84
(3):419-433.
6. European Medicines Agency. PRAC strategy on measuring the impact
of pharmacovigilance activities (Rev 1), EMA/165407/2017. http://
www.ema.europa.eu/docs/en_GB/document_library/Other/2016/
01/WC500199756.pdf. Accessed April 30, 2019.
7. European Commission. European Medicines Agency and Member
States joint report to the European Commission on the experience with
the list of products subject to additional monitoring. https://ec.europa.
eu/health/sites/health/files/files/pharmacovigilance/docs/2019_ema-
ms_additional-monitoring_en.pdf. Accessed November 19, 2019.
8. European Medicines Agency. 2018 Annual Report on EudraVigilance
for the European Parliament, the Council and the Commission.
https://www.ema.europa.eu/en/documents/report/2018-annual-rep
ort-eudravigilance-european-parliament-council-commission-reportin
g-period-1-january_en.pdf. Accessed July 18, 2019.
9. European Medines Agency. EudraVigilance. https://www.ema.europa.
eu/en/human-regulatory/research-development/pharmacovigilance/
eudravigilance. Accessed July 24, 2019.
10. Postigo R, Brosch S, Slattery J, et al. EudraVigilance medicines safety
database: publicly accessible data for research and public health pro-
tection. Drug Saf. 2018;41(7):665-675.
11. European Medicines Agency. Guideline on good pharmacovigilance
practices (GVP)—Module VII – Periodic safety update report (Rev 1).
https://www.ema.europa.eu/en/documents/scientific-guideline/
guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-
safety-update-report_en.pdf. Accessed April 30, 2019.
12. Register of Medicinal Product Statistics. www.medstat.dk.
13. Health Insurance system. http://www.ameli.fr/l-assurance-maladie/
statistiques-et-publications/donnees-statistiques/medicament/
medic-am/medic-am-mensuel-2016.php.
14. The Drug Information System of National Health Care Institute (GIP
Databank). www.gipdatabank.nl.
15. Norwegian Prescription Database (NorPD). http://www.norpd.no.
16. Statistikdatabas för läkemedel. http://www.socialstyrelsen.se/
statistik/statistikdatabas/lakemedel.
17. National Health Service/Information Services Division Scotland. http://
www.isdscotland.org/Health-Topics/Prescribing-and-medicines/Commu
nity-Dispensing/Prescription-Cost-Analysis/. Welsh Government: http:
//gov.wales/statistics-and-research/prescriptions-dispensed-community
/?tab=previous&lang=en. National Health Service (NHS) Digital: https://
data.gov.uk/dataset/prescription-cost-analysis-england.
18. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series
regression for the evaluation of public health interventions: a tutorial.
Int J Epidemiol. 2017;46(1):348-355.
19. Bhaskaran K, Gasparrini A, Hajat S, Smeeth L, Armstrong B. Time
series regression studies in environmental epidemiology. Int J
Epidemiol. 2013;42:1187-1195.
20. U.S. Department of Health and Human Services—National Institutes
of Health—National Cancer Institute: Joinpoint. https://surveillance.
cancer.gov/joinpoint/. Accessed July 24, 2019.
21. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint
regression with applications to cancer rates. Stat Med. 2000;19:335-351.
22. European Medicines Agency. Xgeva European Public Assessment
Report. https://www.ema.europa.eu/en/medicines/human/EPAR/
xgeva. Accessed July 18, 2019.
23. European Medicines Agency. Prolia European Public Assessment
Report. https://www.ema.europa.eu/en/medicines/human/EPAR/
prolia. Accessed July 18, 2019.
24. Patrignani A, Palmieri G, Ciampani N, Moretti V, Mariani A, Racca L.
Under-reporting of adverse drug reactions, a problem that also
involves medicines subject to additional monitoring. Preliminary data
from a single-center experience on novel oral anticoagulants. G Ital
Cardiol. 2018;19(1):54-61.
25. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a sys-
tematic review. Drug Saf. 2006;29(5):385-396.
26. Varallo FR, Guimar~aes SOP, Abjaude SAR, Mastroianni PC. Causes for
the underreporting of adverse drug events by health professionals: a
systematic review. Rev Esc Enferm USP. 2014;48(4):739-747.
27. Al Dweik R et al. Factors affecting patient reporting of adverse drug
reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):
875-883.
28. O'Callaghan J et al. Knowledge of adverse drug reaction reporting
and the pharmacovigilance of biological medicines: a survey of
healthcare professionals in Ireland. BioDrugs. 2018;32(3):267-280.
How to cite this article: Segec A, Slattery J, Morales DR,
Januskiene J, Kurz X, Arlett P. Does additional monitoring
status increase the reporting of adverse drug reactions? An
interrupted time series analysis of EudraVigilance data.
Pharmacoepidemiol Drug Saf. 2020;1–10. https://doi.org/10.
1002/pds.5174
10 SEGEC ET AL.
